Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Epilepsy Patients May Have Poor Bone Health, High Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2016

GENERIC_Drugs_500x270In a recent research review, Sandra J. Petty, honorary research fellow at the Melbourne Brain Centre, The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, and colleagues sought to better understand and define an increased fracture rate associated with epilepsy and its treatment.1 Studies in these patients have mostly varied in quality, making it difficult to determine definitive results. Many studies have shown that these patients have decreases in bone, developing osteoporosis and/or osteomalacia, along with a high prevalence of vitamin D insufficiency and deficiency. The risk of falling is higher for epileptics taking anti-seizure epileptic medications, who may suffer subsequent fractures after falling.

Of note, epileptic patients also have the same risk factors as non-epileptics for fracture and osteoporosis, such as being smokers, having a family history, use of glucocorticoids, early menopause and low physical activity. Because of the many uses for anti-epileptic drugs, such as migraine, chronic pain and bipolar disorder, the association between anti-epileptic drugs, epilepsy and bone health warrant further investigation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators searched the medical literature for articles and abstracts pertaining to anti-epileptic and individual drugs, epilepsy, osteoporosis and bone fractures. They noted that, often, bone mineral density is not reported in epilepsy studies evaluating fracture. It is, therefore, recommended that longitudinal studies of bone microarchitecture be conducted to help determine bone quality associated with epilepsy and its treatment. In addition, larger research collaborations are recommended to advance understanding, particularly as it relates to examining the underlying genetics and pharmacogenomic associations of epilepsy and its treatment in connection with bone disease and fractures. Optimal management of bone health in epilepsy also requires further investigation and evaluation.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Petty SJ, Wilding H, Wark JD. Osteoporosis associated with epilepsy and the use of anti-epileptics—a review. Curr Osteoporos Rep. 2016 Apr;14(2):54–65. doi: 10.1007/s11914-016-0302-7.

Share: 

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:anti-epletic drugsbonebone mineral density (BMD)EpilepsyFracturesOsteoporosis

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Prevent Osteoporotic Fractures with a Fracture Liaison Service

    May 18, 2019

    Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences